{"id":"gp681","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:04:46.268412","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GP681 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"GP681 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:39:15.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"_fixedFields":["pubmed(7)"],"trialDetails":[{"nctId":"NCT06643156","phase":"PHASE1","title":"Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-09-27","conditions":"Influenza","enrollment":44},{"nctId":"NCT06678542","phase":"PHASE1","title":"Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-09-27","conditions":"Healthy Participants","enrollment":36},{"nctId":"NCT06574503","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza","status":"RECRUITING","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-12-01","conditions":"Influenza","enrollment":748},{"nctId":"NCT06573008","phase":"PHASE3","title":"Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications","status":"RECRUITING","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-11-11","conditions":"Influenza, Human","enrollment":328},{"nctId":"NCT05814926","phase":"PHASE1","title":"GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2023-04-26","conditions":"Healthy Volunteers, Hepatic Impairment","enrollment":24},{"nctId":"NCT05474755","phase":"PHASE3","title":"To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2022-07-28","conditions":"Influenza","enrollment":591},{"nctId":"NCT05789342","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2023-02-15","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT04736758","phase":"PHASE2","title":"A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2021-01-08","conditions":"Influenza","enrollment":216},{"nctId":"NCT05103241","phase":"PHASE1","title":"A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2021-10-26","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT04729764","phase":"PHASE1","title":"Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2020-08-27","conditions":"Influenza","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"recentPublications":[{"date":"2026 Mar 23","pmid":"41870058","title":"A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2026 Mar 12","pmid":"41820042","title":"[Annual review of community-acquired pneumonia (CAP) 2025].","journal":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases"},{"date":"2025 Dec","pmid":"41550640","title":"Physiologically based pharmacokinetic (PBPK) modeling of drug-drug interactions between suraxavir marboxil and CYP3A4 inhibitors: Quantitative prediction of pharmacokinetic effects on active metabolite GP1707D07.","journal":"Pharmaceutical science advances"},{"date":"2025 Nov 5","pmid":"41025645","title":"A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2024","pmid":"40291342","title":"Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism.","journal":"Frontiers in pharmacology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reference treatment"],"phase":"phase_2","status":"active","brandName":"GP681","genericName":"GP681","companyName":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","companyId":"jiangxi-qingfeng-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP681 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}